YOLFTbeta
Benitec Biopharma Ltd ADR

Benitec Biopharma Ltd ADR

BNTC · NASDAQ · Healthcare / Biotechnology

9.04USD-0.05 (-0.55%)

Price History

Full chart

Market Stats

Previous Close9.09
Open9.17
Day Range8.69 – 9.36
52-Week Range9.26 – 16.76
Volume144.69K
Market Cap336.27M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.96
Dividend Yield0.00%
Beta0.27
50-Day Avg12.22
200-Day Avg12.00

About

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jerel A. Banks M.D., Ph.D.
  • Employees24
  • Headquarters3940 Trust Way, Hayward, CA, United States, 94545, USA
  • Websitehttps://benitec.com

Leadership

  • Dr. Jerel A. Banks M.D., Ph.D.Executive Chairman & CEO · b. 1976
  • Ms. Megan Joan Boston B.Com., C.A.CFO & Secretary · b. 1973
  • Ms. Sophie MukadamChief Operating Officer · b. 1981
  • Dr. Michael GrahamHead of Discovery & Founding Scientist
  • Dr. Claudia Kloth Ph.D.Senior Vice President of Manufacturing

Financials

Income Statement

Currency: USD2004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue92.91K523.41K2.34M372.42K268.05K215.63K157.65K144.33K329.71K504.45K956.15K630.50K258.52K195.88K4.40M17.45M97.00K59.00K73.00K75.00K216.00K00
Growth (%)-+463.36%+347.48%-84.10%-28.02%-19.56%-26.89%-8.45%+128.44%+53.00%+89.54%-34.06%-59.00%-24.23%+2146.54%+296.49%-99.44%-39.18%+23.73%+2.74%+188.00%-100.00%-
Cost of Revenue-1.38M-1.21M2.55M1.65M1.60M1.02M1.19M162.81K35.38K23.33K77.44K160.00K473.96K622.17K-185.00K123.00K9.00K381.00K343.00K396.00K481.00K
Gross Profit--854.04K2.34M-835.00K-2.28M-1.44M-1.44M-873.06K-856.35K341.64K920.77K607.17K181.07K35.88K3.95M15.90M282.00K-64.00K64.00K75.00K-343.00K-396.00K-481.00K
Gross Margin--163.17%100.00%-224.21%-849.98%-666.67%-915.10%-604.90%-259.73%67.73%96.30%96.30%70.04%18.32%89.70%91.12%290.72%-108.47%87.67%100.00%-158.80%--
Operating Expense-13.74M4.27M456.98K502.98K1.04M1.26M2.00M3.52M7.88M14.45M10.74M18.81M15.97M12.68M12.20M8.56M13.53M17.92M19.16M22.15M41.37M50.71M
Operating Income-8.65M-14.60M-1.93M-1.29M-2.78M-2.48M-2.71M-2.88M-4.37M-7.54M-13.53M-10.14M-18.62M-15.93M-8.73M3.69M-8.28M-13.60M-17.85M-19.08M-22.49M-41.77M-51.19M
Operating Margin-9311.01%-2788.47%-82.26%-346.92%-1037.62%-1148.15%-1716.46%-1992.62%-1325.88%-1494.87%-1414.88%-1607.60%-7204.22%-8132.38%-198.38%21.17%-8537.11%-23044.07%-24457.53%-25441.33%-10412.04%--
EBITDA-7.02M-13.15M-1.93M-1.29M-2.78M-2.47M-2.70M-2.87M-4.36M-6.23M-9.74M-6.03M-21.05M-3.21M-6.32M1.92M-7.91M-13.45M-17.78M-18.70M-22.15M-41.37M-50.71M
EBITDA Margin-7555.55%-2511.63%-82.26%-346.39%-1035.96%-1145.84%-1714.02%-1986.84%-1321.92%-1234.45%-1018.59%-956.62%-8142.21%-1637.54%-143.64%10.98%-8151.55%-22800.00%-24361.64%-24933.33%-10253.24%--
Net Income-7.90M-14.08M-7.77M-2.54M-2.59M-2.28M-4.84M-3.26M-4.19M-3.87M-6.87M-6.71M-13.81M-5.60M-12.33M3.73M-8.27M-13.88M-18.21M-19.56M-21.75M-37.92M-45.55M
Net Income Margin-8507.74%-2689.77%-331.80%-682.28%-965.54%-1055.51%-3069.91%-2255.80%-1270.98%-766.75%-718.19%-1064.66%-5340.11%-2860.43%-280.13%21.39%-8529.90%-23528.81%-24942.47%-26082.67%-10069.91%--
R&D1.02M3.00M2.18M-555.00K1.04M1.26M1.18M1.33M3.17M5.51M3.63M7.40M4.07M3.73M3.19M3.00M7.02M11.27M12.77M15.61M18.33M23.39M
R&D as % of Total Revenue1096.75%574.00%93.07%-207.05%481.48%801.36%817.04%404.59%628.43%576.13%576.13%2863.59%2079.58%84.66%18.30%3093.81%11898.31%15441.10%17032.00%7226.39%--
Interest Expense36.36K192.57K-1.94K8.76K3.67K58.80K26.82K8.68K000000119.06K62.00K6.00K32.00K33.00K904.00K3.29M-
Interest Expense % of Total Revenue39.13%36.79%-0.52%3.27%1.70%37.30%18.59%2.63%0.00%0.00%0.00%0.00%0.00%0.00%0.68%63.92%10.17%43.84%44.00%418.52%--

Balance Sheet

Currency: USD2004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets--2.30M5.22M2.02M2.02M1.04M6.87M3.29M31.48M24.03M25.82M19.86M22.75M21.45M27.51M11.74M21.38M5.97M4.46M52.21M99.59M182.62M
Total Liabilities--2.24M1.57M662.63K859.06K1.74M1.66M595.77K871.53K1.55M1.26M1.05M891.40K2.61M2.64M1.51M1.37M3.09M4.26M4.96M2.30M5.61M
Total Equity--63.03K3.64M1.36M1.16M-697.45K5.21M2.70M30.61M22.48M18.31M14.07M21.58M13.77M16.57M10.24M20.01M2.88M202.00K47.25M97.30M177.01M
Cash--906.44K4.96M207.92K220.97K172.85K6.66M3.12M28.62M20.51M22.04M18.20M17.44M16.17M22.48M9.80M19.77M4.06M2.48M50.87M97.74M179.97M
Total Debt---186.60K--460.17K292.74K----0000405.00K213.00K811.00K559.00K284.00K849.00K762.00K
Net Debt---906.44K-4.78M-207.92K-220.97K287.31K-6.37M-3.12M-28.62M-20.51M-16.71M-13.61M-13.35M-11.82M-15.70M-9.40M-19.56M-3.25M-1.92M-50.58M-96.89M-179.21M

Cash Flow

Currency: USD2004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-8.84M-13.05M-8.37M-1.75M-2.88M-1.98M-2.43M-2.93M-3.22M-3.03M-9.04M-9.69M-20.21M-8.30M-9.79M4.79M-7.54M-12.83M-15.90M-18.01M-19.40M-23.59M-16.52M
Investing Cash Flow-328.21K-763.23K-11.85K-8.35K-10.07K-165-2.63K-25.69K-18.17K148.28K-31.57K-387.33K-342.00K-302.00K-147.00K-399.19K-94.00K-221.00K-13.00K-1.00K-179.00K-18.00K-105.00K
Financing Cash Flow13.70M15.20M3.12M5.54M13.17K1.97M1.17M8.50M-411.48K1.21M38.12M56.95K17.51M7.94M8.51M-688.11K1.77M22.52M16.02M16.02M68.03M70.48M98.98M
Capital Expenditure56.55K802.69K11.85K8.35K10.07K1662.64K25.69K18.17K29.20K475.45K387.33K255.40K131.41K60.97K403.39K95.00K221.00K13.00K1.00K179.00K18.00K105.00K
Free Cash Flow-8.90M-13.85M-8.39M-1.76M-2.89M-1.98M-2.43M-2.95M-3.24M-9.30M-10.17M-10.08M-20.46M-8.44M-8.61M4.39M-7.63M-13.05M-15.91M-18.01M-19.58M-23.61M-16.62M
Dividends Paid-----------00000----619.00K--
FCF to OCF100.64%106.15%100.14%100.48%100.35%100.01%100.11%100.88%100.56%306.91%112.43%104.00%101.26%101.58%87.93%91.58%101.26%101.72%100.08%100.01%100.92%100.08%100.64%
Dividend Paid to FCF-----------0.00%0.00%0.00%0.00%0.00%-----3.16%--

Earnings

Report DateFeb 26, 2016May 24, 2016Nov 22, 2016Nov 29, 2017Feb 22, 2018May 31, 2018Aug 30, 2018Nov 20, 2018Feb 25, 2019Apr 24, 2019Aug 29, 2019Nov 19, 2019Jan 31, 2020May 27, 2020Aug 14, 2020Nov 13, 2020Feb 9, 2021May 12, 2021Sep 20, 2021Nov 15, 2021Feb 14, 2022May 16, 2022Sep 2, 2022Nov 10, 2022Feb 13, 2023May 15, 2023Sep 21, 2023Nov 13, 2023Feb 13, 2024May 13, 2024Sep 19, 2024Nov 14, 2024Feb 14, 2025May 14, 2025Sep 22, 2025Nov 14, 2025Feb 12, 2026May 14, 2026Sep 14, 2026Nov 13, 2026
EPS Estimate0.00---0.00--0.00------0.01-0.01-15.64-12.75-0.85-0.93-128.15-104.47-7.48-0.28-4.25-1.87-3.40-3.23-0.51-0.39-0.78-0.49-0.55-0.78-0.35-0.31-76.32-0.23-0.28-0.26-0.28
EPS Actual0.00-2.390.00-0.020.00-0.01-0.030.000.04-1.99-0.02-1.34-0.02-0.01-2.94-41.65-12.92-0.82-0.57-0.62-0.59-6.80-0.62-7.99-3.40-2.72-2.83-2.76-2.64-1.64-1.32-0.48-0.33-0.24-0.42-0.22-0.26-0.24-0.26-
Surprise-------------0.00%-29300.00%-166.30%-1.33%3.53%38.71%99.52%99.44%9.09%-121.43%-88.00%-81.82%20.00%12.38%-441.18%-576.92%-110.26%-169.39%12.73%57.69%31.43%-35.48%99.71%-13.04%14.29%0.00%-
TimingPre-marketAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hours-After-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hours-Pre-marketPre-marketAfter-hours-

Key Statistics & Ratios

Market Cap336.27M
Enterprise Value164.38M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales2770.13
Price / Book1.94
EPS-0.96
Book Value5.14
Revenue (TTM)7.00K
Gross Profit (TTM)0
EBITDA-51.13M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-33.21%
Return on Assets-22.67%
Shares Outstanding34.88M
Shares Float18.45M
Beta0.27
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 24.33
  • Strong Buy
    4
  • Buy
    3

Ownership Breakdown

Institutions
98.96%
Insiders
2.51%
Retail / Other
0.00%

Top Institutional Holders

  • Suvretta Capital Management, LLC
    11.55M33.62%
  • HHG PLC
    2.88M8.37%
  • Franklin Templeton Inc
    2.38M6.92%
  • Adage Capital Partners Gp LLC
    2.12M6.17%
  • RA Capital Management, LLC
    1.85M5.39%
  • Nantahala Capital Management, LLC
    1.44M4.19%
  • BlackRock Inc
    1.19M3.45%
  • Simplify Asset Management Inc.
    1.01M2.93%
  • Vanguard Capital Management, LLC
    931.56K2.71%
  • Millennium Management LLC
    921.30K2.68%
  • Alyeska Investment Group, L.P.
    750.00K2.18%
  • SILVERARC CAPITAL MANAGEMENT, LLC
    717.73K2.09%
  • Balyasny Asset Management LLC
    653.84K1.90%
  • Geode Capital Management, LLC
    524.10K1.53%

Top Fund Holders

  • HBM Healthcare Investments AG Ord
    1.19M3.46%
  • Simplify Health Care ETF
    1.06M3.07%
  • Franklin Biotechnology Discv A(acc)USD
    997.48K2.90%
  • Franklin Biotechnology Discovery A
    995.15K2.89%
  • Vanguard MStar Total Stk Mkt Idx Invest
    649.54K1.89%
  • iShares Russell 2000 ETF
    525.45K1.53%

Dividends

20181×
0.77Jun 1, 2018

Stock Splits

  • Jul 26, 20231:17
  • Apr 15, 20202:3
  • Nov 18, 20191:10
  • Jun 16, 20151:4